|
US2020190045A1
|
|
Ferroportin inhibitors and methods of use
|
|
WO2020106642A1
|
|
2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
|
|
US2020140384A1
|
|
Modulators of hemoglobin
|
|
US2019300477A1
|
|
Compounds and uses thereof for the modulation of hemoglobin
|
|
WO2019036384A1
|
|
Tricyclic compounds as histone methyltransferase inhibitors
|
|
WO2019036377A1
|
|
Tricyclic compounds as histone methyl-transferase inhibitors
|
|
US2018354947A1
|
|
Azaindole compounds as histone methyltransferase inhibitors
|
|
US2018186745A1
|
|
Histone methyltransferase inhibitors
|
|
TW201815384A
|
|
Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
|
TW201741295A
|
|
Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
|
|
WO2017142947A1
|
|
Histone methyltransferase inhibitors
|
|
SG10201912511WA
|
|
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
|
US2016362427A1
|
|
Bridged bicyclic kallikrein inhibitors
|
|
WO2016160755A1
|
|
Aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease
|
|
JO3562B1
|
|
Crystalline polymorphs of the free base of 2?hydroxy?6?((2?(1?isopropyl?1h?pyrazol?5?yl)pyridin?3?yl)methoxy)benzaldehyde
|
|
WO2016043849A2
|
|
Compounds for treating acute respiratory distress syndrome or a negative effect thereof
|
|
WO2015171527A1
|
|
Pyrazolopyridine pyrazolopyrimidine and related compounds
|
|
WO2015171526A2
|
|
Tricyclic pyrazolopyridine compounds
|
|
SG11201510135XA
|
|
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
|
US2015141465A1
|
|
Compounds and uses thereof for the modulation of hemoglobin
|
